Publications by authors named "Nancy Davis"

Claim this Profile
E
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.
Tanya Jindal, Cindy Y Jiang, Omar Alhalabi, Matthew Davidsohn, Dory Freeman, Nancy B Davis

Urol Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.
Cindy Y Jiang, Hyunsoo Hwang, Ilana Y Epstein, Dimitra Rafailia Bakaloudi, Rafee Talukder, Nancy B Davis

Oncologist· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy.
Petros Grivas, Scott T Tagawa, Rohit K Jain, Manojkumar Bupathi, Arjun Balar, Nancy Davis

Future Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.
Amanda Nizam, Charles B Nguyen, Jinju Li, Emily C Zabor, Pavlos Msaouel, Nancy B Davis

Cancer Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.
Tanya Jindal, Cindy Y Jiang, Omar Alhalabi, Charles B Nguyen, Eugene Oh, Nancy B Davis

Eur Urol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
Tanya Jindal, Cindy Jiang, Omar Alhalabi, Amanda Nizam, Charles Nguyen, Nancy B Davis

Eur Urol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.
Daniel P Petrylak, Scott T Tagawa, Rohit K Jain, Manojkumar Bupathi, Arjun Balar, Nancy Davis

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: Bladder preservation options for bladder cancer.
Nancy B Davis, Deepak Kilari, Elizabeth R Kessler, Woodson W Smelser

Front Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Pavlos Msaouel, Randy F Sweis, Manojkumar Bupathi, Elisabeth Heath, Oscar B Goodman, Nancy Davis

Eur Urol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.
Petros Grivas, Damien Pouessel, Chandler H Park, Philippe Barthelemy, Manojkumar Bupathi, Nancy B Davis

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
Talal El Zarif, Amin H Nassar, Gregory R Pond, Tony Zibo Zhuang, Viraj Master, Nancy B Davis

J Natl Cancer Inst· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin.
Catherine C Fahey, Caroline A Nebhan, Sally York, Nancy B Davis, Paula J Hurley

Int J Mol Sci· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Therapy for Melanoma: ASCO Guideline Update.
Rahul Seth, Sanjiv S Agarwala, Hans Messersmith, Krishna C Alluri, Paolo A Ascierto, Nancy Davis

J Clin Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
Joseph W Kim, Rana R McKay, Marc R Radke, Shilin Zhao, Mary-Ellen Taplin, Nancy B Davis

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
Nizar M Tannir, Neeraj Agarwal, Camillo Porta, Nicola J Lawrence, Robert Motzer, Nancy Davis

JAMA Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.
Yu-Wei Chen, Matthew D Tucker, Landon C Brown, Hesham A Yasin, Kristin K Ancell, Nancy B Davis

Cancers (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Vadim S Koshkin, Nicholas Henderson, Marihella James, Divya Natesan, Dory Freeman, Nancy B Davis

Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.
Matthew D Tucker, Landon C Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman, Nancy B Davis

Biomark Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review-based cohort study.
Kyle A Dymanus, Mohit Butaney, Diana E Magee, Amanda E Hird, Amy N Luckenbaugh, Nancy B Davis

Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma.
Eileen Shiuan, Anupama Reddy, Stephanie O Dudzinski, Aaron R Lim, Ayaka Sugiura, Nancy B Davis

Cancers (Basel)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes With Liver-Directed Therapy for Genitourinary Malignancies: Single-Institution Experience.
Michael Pierro, Ruben Raychaudhuri, William B Lea, William Rilling, Nancy Davis

Clin Genitourin Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports.
Matthew D Tucker, Kathryn E Beckermann, Jennifer B Gordetsky, Giovanna A Giannico, Nancy B Davis

Front Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Therapy for Melanoma: ASCO Guideline.
Rahul Seth, Hans Messersmith, Varinder Kaur, John M Kirkwood, Ragini Kudchadkar, Nancy Davis

J Clin Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma.
Christopher G Wood, James E Ferguson, Joel S Parker, Dominic T Moore, Jennifer G Whisenant, Nancy B Davis

JCI Insight· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.
Matthew D Galsky, Amir Mortazavi, Matthew I Milowsky, Saby George, Sumati Gupta, Nancy Davis

J Clin Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis